The Friend spleen focus-forming virus (SFFV) causes an acute erythroleukemia in susceptible strains of mice (for a review, see reference 37). SFFV encodes a unique envelope glycoprotein, gp55, that associates specifically with the erythropoietin receptor (EpoR) at the cell surface (4, 10, 21, 45), allowing erythroid cells to proliferate in the absence of erythropoietin (Epo), the normal regulator of erythropoiesis. Epo stimulation of the EpoR activates a number of signal transduction pathways, including the Jak-Stat, the Ras/Raf-1/mitogen-activated protein kinase (MAPK), and the phosphatidylinositol 3-kinase (PI3-kinase) pathways (for a review, see reference 46). Using the Epo-dependent erythroleukemia cell line HCD-57, we have previously demonstrated that infection with SFFV, which abrogates the Epo dependence of these cells (36), constitutively activates Stat DNA-binding activity (30); Ras (27); Raf-1, MEK, and MAPK (26); PI 3-kinase and Akt kinase (29); and protein kinase C (27). Although interaction of the SFFV envelope glycoprotein with the EpoR complex is essential for inducing the biological effects of the virus, other factors must also be involved, since not all strains of mice are susceptible to SFFV-induced erythroleukemia. A number of polymorphic mouse genes have been identified that affect susceptibility to Friend SFFV-induced erythroleukemia. Most of these host genes interfere with viral entry or integration, or they control immune responses against the virus-infected cells (for a review, see reference 7). However, the Fv-2 gene (22), which is located on mouse chromosome 9, acts at the level of the erythroid target cell for the virus (2, 3, 9, 13, 39). Mice carrying at least one copy of the Fv-2s allele are susceptible to SFFV-induced erythroleukemia, and their erythroid cells will form Epo-independent erythroid bursts when infected in vitro with SFFV. In contrast, mice homozygous for the Fv-2r allele fail to develop SFFV-induced erythroleukemia, and SFFV infection of erythroid cells from these mice does not result in the formation of Epo-independent erythroid bursts. Thus, erythroid cells from Fv-2-resistant mice appear to lack a component necessary for mediating the biological effects of SFFV infection. Although earlier studies suggested that there were differences between Fv-2-susceptible and -resistant erythroid cells in cell cycling (42), it was unclear how this affected the ability of SFFV to alter the growth of these cells. Recently, however, it was shown that the Fv-2 gene is identical to the gene encoding the Met-related tyrosine kinase Stk/Ron (33). Mice that carry the Fv-2s allele express both a full-length Stk and a truncated form of the kinase, sf-Stk, which is expressed from an alternate promoter. sf-Stk lacks almost the entire extracellular domain but retains the transmembrane and tyrosine kinase domains. In contrast to Fv-2s mice, mice that are homozygous for the Fv-2r allele express only full-length Stk due to a 3-nucleotide deletion in the alternate promoter. Transfer of bone marrow cells expressing sf-Stk to Fv-2rr mice confers susceptibility to SFFV-induced erythroleukemia, while targeted disruption of the Stk gene in Fv-2s mice results in resistance to disease (33). Thus, expression of sf-Stk in erythroid cells appears to play a critical role in determining the biological consequences of SFFV infection in the mouse. We, therefore, carried out studies to determine if SFFV gp55 interacts with sf-Stk and whether this interaction results in the activation of this truncated kinase and the downstream activation of signal transduction pathways.